Catalyst Pharmaceuticals Inc (CPRX) Earns Buy Rating from HC Wainwright
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday. They presently have a $6.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 261.45% from the stock’s current price.
Separately, Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, January 5th.
Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) traded up 7.79% during mid-day trading on Monday, hitting $1.66. 3,994,589 shares of the company’s stock traded hands. The firm has a 50-day moving average of $1.17 and a 200 day moving average of $1.14. The company’s market cap is $137.56 million. Catalyst Pharmaceuticals has a 52 week low of $0.51 and a 52 week high of $1.81.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, March 15th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.02. Equities research analysts predict that Catalyst Pharmaceuticals will post ($0.26) EPS for the current year.
Your IP Address:
Hedge funds have recently bought and sold shares of the company. Berson & Corrado Investment Advisors LLC raised its stake in Catalyst Pharmaceuticals by 76.1% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 181,900 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 78,600 shares in the last quarter. Royal Bank of Canada purchased a new stake in Catalyst Pharmaceuticals during the second quarter valued at about $117,000. Kingdon Capital Management L.L.C. purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at about $794,000. Finally, Baker BROS. Advisors LP purchased a new stake in Catalyst Pharmaceuticals during the third quarter valued at about $5,561,000. Institutional investors and hedge funds own 28.13% of the company’s stock.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.